Innovent Biologics, Inc. Expands Phase 3 MarsLight-11 to Non-Squamous NSCLC

Innovent expanded its global Phase 3 MarsLight-11 trial of IBI363/TAK-928 in immunotherapy-resistant NSCLC to add a non-squamous substudy, alongside the existing squamous cohort, comparing IBI363 monotherapy vs docetaxel.Material DetailsContext by AI AnalystThis is a mid-cycle development update ex…